Overview

Pleotropic Effect of New Oral Anticoagulants

Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel. This study was designed to determine the efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of atherosclerosis of AF subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Kyunghee University Medical Center
Treatments:
Anticoagulants
Dabigatran
Warfarin